Kerttu Kalander

Figure S8. In vitro and in vivo activity of low a7inity scFv-guided CAR (KD = 3910 nM).

Figure S13. SKOV3 ovarian tumor volume measurements of individual mice treated with T cells expressing constitutive or inducible Sb1205 anti-HER2 CAR (related to Figure 5B and C).

Figure S3. Antigen expression and HER2 knock-down in a panel of cancer cell lines and additional Jurkat T cell reporter activation (NFAT-GFP) assays in co-culture with 293T* (HER2 KD) cells transfected with tumor associated antigens (related to Figure 2C, 2D.

Figure S5. Cytotoxic activity of Sb CARs expressed in human primary CD8+ T cells (related to Figure 2E)

Figure S9. Tumor volume measurement of individual mice treated with T cells expressing Sb1205 anti-HER2 CAR (related to Figure 4C and E).

Nucleotide sequences of constructs used in the study

Figure S4. NFAT-EGFP reporter activation in Jurkat T cells exposed to phorbol myristateacetate (PMA) and ionomycin or co-cultured with target cells expressing the cognate tumor associated antigen.

Figure S12. Statistical analysis of fraction of CD62L+CD45RA+ in T cells engineered with constitutive ScFv and SbCAR and inducible SbCAR (related to Figure 5A).

Figure S14. HCC1569 breast tumor volume measurements of individual mice treated with T cells expressing constitutive or inducible Sb1205 anti-HER2 CAR (related to Figure 5B).

Supplementary Figure 1. Binding specificity of sherpabodies against a panel of promiscuouslyinteracting macromolecules